Related Experiment Videos
Response rates--an evolution
Abstract:
The documented frequency of response of cancers to common chemotherapy agents and combinations appears to have decreased over the decades. Multiple reasons exist for this decline including: changes in eligibility and evaluability criteria; changes in the type of patients entered onto trial; and, altered criteria for response and methods for response assessment. The disinclination to publish negative results also permits a bias in a favor of overestimating a drug's efficacy. Circumspection now is advised in assessing data from older trials.
Insights
Cancer treatment effectiveness may be declining due to changes in trial criteria and reporting biases. Careful review of older chemotherapy trial data is now recommended for accurate efficacy assessment.
Area of Science:
- Oncology
- Clinical Trials
- Chemotherapy Research
Background:
- Documented response rates to chemotherapy have seemingly decreased over recent decades.
- Several factors may contribute to this observed decline in treatment efficacy.
Purpose of the Study:
- To analyze the potential reasons behind the decreasing frequency of cancer response to chemotherapy.
- To highlight biases that may affect the interpretation of chemotherapy trial data.
Main Methods:
- Review of historical trends in cancer clinical trial eligibility and response assessment criteria.
- Analysis of factors influencing patient selection and data evaluation in chemotherapy studies.
- Examination of publication bias related to negative trial outcomes.
Main Results:
- Changes in eligibility, evaluability, and response criteria have impacted reported outcomes.
- Patient population shifts and altered response assessment methods contribute to perceived efficacy decline.
- The tendency to not publish negative results creates an overestimation bias for drug efficacy.
Conclusions:
- The apparent decrease in chemotherapy response rates necessitates critical evaluation of historical data.
- Researchers and clinicians should exercise caution when interpreting findings from older chemotherapy trials.
- Understanding methodological and reporting changes is crucial for accurate cancer drug efficacy assessment.